- Home
- RPAY vs LAB Comparison
RPAY vs LAB Comparison
Compare RPAY & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPAY
- LAB
- Stock Information
- Founded
- RPAY 2006
- LAB 1999
- Country
- RPAY United States
- LAB United States
- Employees
- RPAY N/A
- LAB N/A
- Industry
- RPAY Business Services
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- RPAY Consumer Discretionary
- LAB Industrials
- Exchange
- RPAY Nasdaq
- LAB Nasdaq
- Market Cap
- RPAY 665.4M
- LAB 562.1M
- IPO Year
- RPAY N/A
- LAB 2011
- Fundamental
- Price
- RPAY $7.37
- LAB $1.77
- Analyst Decision
- RPAY Strong Buy
- LAB Strong Buy
- Analyst Count
- RPAY 6
- LAB 2
- Target Price
- RPAY $12.33
- LAB $2.88
- AVG Volume (30 Days)
- RPAY 541.0K
- LAB 1.7M
- Earning Date
- RPAY 02-27-2025
- LAB 02-26-2025
- Dividend Yield
- RPAY N/A
- LAB N/A
- EPS Growth
- RPAY N/A
- LAB N/A
- EPS
- RPAY N/A
- LAB N/A
- Revenue
- RPAY $310,758,000.00
- LAB $155,902,000.00
- Revenue This Year
- RPAY $9.03
- LAB $62.60
- Revenue Next Year
- RPAY $5.59
- LAB $9.19
- P/E Ratio
- RPAY N/A
- LAB N/A
- Revenue Growth
- RPAY 5.95
- LAB 48.23
- 52 Week Low
- RPAY $7.04
- LAB $1.21
- 52 Week High
- RPAY $11.27
- LAB $3.04
- Technical
- Relative Strength Index (RSI)
- RPAY 38.61
- LAB 46.48
- Support Level
- RPAY $7.15
- LAB $1.67
- Resistance Level
- RPAY $7.67
- LAB $2.14
- Average True Range (ATR)
- RPAY 0.21
- LAB 0.15
- MACD
- RPAY -0.01
- LAB -0.00
- Stochastic Oscillator
- RPAY 30.14
- LAB 32.73
About RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segment, Consumer Payment and Business Payments.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.